Key result
Only ~20% of patients prescribed chronic antipsychotics receive standard yearly cardiometabolic monitoring.
Why the study?
Antipsychotics carry significant cardiometabolic adverse event profiles, but adherence to routine guideline-recommended monitoring in primary care is known to be suboptimal.
Are patients prescribed chronic antipsychotic therapy in primary care receiving adequate cardiometabolic monitoring according to guidelines?
Observational (n=497)
Yes
Are patients prescribed chronic antipsychotic therapy in primary care receiving adequate cardiometabolic monitoring according to guidelines?
Answers are grounded in this paper and cite their sources.
Routine cardiometabolic monitoring for primary care patients on antipsychotics is infrequent and fails to meet guideline recommendations, particularly for glucose and comprehensive lipid profiles.
BACKGROUND: Despite their known effectiveness, antipsychotics possess significant cardiometabolic adverse event profiles. Guidelines emphasise routine monitoring, however, practices are known to be suboptimal. AIM: To investigate the level of cardiometabolic monitoring among people prescribed antipsychotic therapy in primary care, and patient-related factors that may influence monitoring patterns. METHOD: Data were collected for patients with mental disorders and prescribed antipsychotics at two general practices in England (February 2016-February 2021). The main outcome measures were the proportion of patients with evidence of monitoring for cardiometabolic parameters (body composition, anthropometrics, lipids, glucose outcomes). Regression analysis was used to explore factors predicting monitoring practices. RESULTS: Data from 497 patients were included. The proportion of patients receiving cardiometabolic monitoring at least once yearly varied across different parameters. Patients were mostly monitored for BP (92.0%), body weight (BMI > 85.0%) and HDL (72.0%), but to a lesser extent for other lipid parameters (non-HDL < 2.0%) and blood glucose (< 2.0%). Ageing (OR:2.0-7.0, p < 0.001) and chronic conditions (e.g., CVD and Type 2 DM, p < 0.05) were associated with frequent cardiometabolic monitoring. Conversely, antipsychotics with high metabolic risks (olanzapine), patients prescribed antipsychotic polypharmacy (≥ 2 antipsychotics) and cardiometabolic dysregulations (e.g., dyslipidaemias) did not improve monitoring frequencies. CONCLUSION: Cardiometabolic health monitoring was generally infrequent, irregular, and did not change in response to abnormal test results or antipsychotic treatment with high cardiometabolic risks, suggesting more efforts need to be made to ensure the guidelines for cardiometabolic monitoring are followed. Future studies should investigate practices by using a large UK primary care database.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2023) conducted an observational in Mental disorders prescribed antipsychotics (n=497). Chronic antipsychotic therapy was evaluated on Proportion of patients with evidence of monitoring for cardiometabolic parameters at least once yearly. Routine cardiometabolic monitoring for patients prescribed antipsychotics was suboptimal, with standard yearly monitoring achieved in only approximately 20% of patients.
Synapse has enriched 10 related papers. Consider them for comparative context: